AZD-6422 is under clinical development by AstraZeneca and currently in Phase I for Gastrointestinal Tumor. According to GlobalData, Phase I drugs for Gastrointestinal Tumor does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the AZD-6422 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AZD-6422 is under development for the treatment of advanced or metastatic CLDN18.2 positive gastrointestinal tumors. The therapeutic candidate comprises T cells genetically engineered to express chimeric antigen receptors (CAR) targeting CLDN18.2 expressing tumor cells.
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly- owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
For a complete picture of AZD-6422’s drug-specific PTSR and LoA scores, buy the report here.